Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813908 | 0.83 | NPC1 (0.38) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| Bromide SCHEMBL12482879 | 0.82 | NPC1 (0.37) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL29096262 | 0.80 | TRIM24 (0.45) | TRIM24TRIM33ALDH1A1NPC1RAB9A | |
| SCHEMBL27618964 | 0.79 | — | — | |
| SCHEMBL28725471 | 0.78 | ALDH1A1 (0.46) | TRIM24TRIM33ALDH1A1NPC1RAB9A | |
| SCHEMBL27618963 | 0.76 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1NPC1RAB9A | |
| SCHEMBL25316781 | 0.76 | NPC1 (0.49) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6127705 | 0.75 | — | — | |
| SCHEMBL5403668 | 0.75 | — | — | |
| SCHEMBL8772644 | 0.74 | ALDH1A1 (0.50) | TRIM24TRIM33ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-54041868-A | — | — | None | — | — | JP | disclosed |
| CN-106661034-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| EP-2527340-B1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2407466-B1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-9062035-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8865714-B2 | Piperazine compound capable of inhibiting prostaglandin D synthase | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8765750-B2 | Piperazine compound having a PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8344150-B2 | Pyrrole end-capped bipyridine assay powder for selective detection of zinc ions and a process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-01-01 | — | — | US | disclosed |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-0159677-B1 | NOVEL 4,5-BIS(4-METHOXYPHENYL)-2-(PYRROL-2-YL)THIAZOLES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KANEBO, LTD. (JP) | 1989-02-22 | — | — | EP | disclosed |
| US-4753956-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4689336-A | Hypoglycemic 5-substituted oxazolidine 2,4-diones | PFIZER INC. (US) | 1987-08-25 | — | — | US | disclosed |
| US-4659726-A | ANTICOAGULANTS | KANEBO, LTD. (JP) | 1987-04-21 | — | — | US | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| EP-0159677-A2 | Novel 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles, process for the preparation thereof and pharmaceutical composition containing the same | KANEBO, LTD. (JP) | 1985-10-30 | — | — | EP | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
| JP-S5441868-A | PRODUCTION OF N-ALKYLPYRROLYL-2-ACETIC ACID | SAGAMI CHEM RES CENTER | 1979-04-03 | — | — | JP | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128394-A1 | PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE | PTGDR, PTGS1, PTGDR2 | TRIM24 4627/4885TRIM33 4670/4885ALDH1A1 360/4885 |
| US-20120309760-A1 | PIPERAZINE COMPOUND HAVING A PGDS INHIBITORY EFFECT | GRIK5, GRK5, KCNJ5 | TRIM24 4107/4885TRIM33 3914/4885ALDH1A1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.